Directorate Change

Proteome Sciences PLC
30 September 2004

                             Proteome Sciences plc


                                 PRESS RELEASE



                                                            30th September, 2004


Following the acquisition of Aventis by Sanofi, the Board of Proteome Sciences
plc is pleased to announce the appointment of Dr. Alf Erik Anton Lindberg to the
Board as a non-executive director, with effect from the 1st October, 2004.



Dr. Lindberg, aged 64, was formerly executive vice-president of research and
development and a board member of Aventis Pasteur and is a Director of
Microscience Limited, Medivir AB, Gemvax AS and Vaxin Inc..



There is no other relevant information pursuant to paragraphs f (i - viii) of
Schedule 2 of the AIM rules which is required to be disclosed in connection with
Dr. Lindberg's appointment.



Dr. Lindberg replaces Dr. W.M.M. Schuller who retires as a non-executive
director, with effect from the 30th September, 2004.



                                    - Ends -





For further information please contact:



Proteome Sciences plc

Christopher Pearce, Chief Executive    [e-mail]

                                       Tel :       [phone]

                                       www.proteomics.com



Public Relations for Proteome Sciences

Ikon Associates                  Adrian Shaw:[e-mail]

                                 Tel :       [phone]

                                 Mobile : [phone]






                      This information is provided by RNS
            The company news service from the London Stock Exchange